{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:02:19Z","timestamp":1792609339518,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012147","name":"Royal Brompton and Harefield NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by presenting our real-world experience of the diagnosis and management of these complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two thousand six hundred and forty-seven (2647) patients were started on ICI treatment between 2014 and 2020. Data from 110 patients referred to the cardio-oncology service with a suspected cvAE was collected prospectively and analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-nine\npatients (3.4%) were confirmed to have cvAEs while on ICI therapy. \nMyocarditis was the most frequent event (33\/89), followed by\ntachyarrhythmia (27\/89), non-inflammatory left ventricular dysfunction (NILVD)\n(15\/89) and pericarditis (7\/89). Results from myocarditis and non-inflammatory left ventricular\ndysfunction cohorts were compared. Myocarditis and NILVD showed significant\ndifferences in respect toof\ntroponin elevation, cardiac magnetic resonance abnormalities and ventricular\nfunction. Dual ICI therapy and other immune related adverse events were more\nfrequently associated with myocarditis than NILVD. There was a significant\ndifference in the median time from starting ICI treatment to presentation with\nmyocarditis versus NILVD (12 vs 26 weeks\n                      <jats:italic>p<\/jats:italic>\n                      = 0.049). Through early recognition\nof myocarditis, prompt treatment with steroids and interruption of ICI, there\nwere no cardiovascular in-hospital deaths. NILVD did not\nrequire steroid treatment and ICI could be restarted safely.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The full spectrum of cardiovascular complications\nin patients with immune checkpoint inhibitors is much broader than initially\ndescribed. Myocarditis remains the most frequent cvAE related to ICI treatment.\nA novel type of myocardial injury was observed and\ndefined as Atrial tachyarrhythmias and NILVD\nwere also frequent in this cohort. NILVD has a This\ndiffers fromdifferent presentation from\nICI-related myocarditis, mainly usually\npresenting afterby the lack of\ninflammatory features on CMR and biomarkers and\na later presentation in time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-022-00147-w","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:12:45Z","timestamp":1669295565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment"],"prefix":"10.1186","volume":"8","author":[{"given":"Maria Sol","family":"Andres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivatharshini","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Baksi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajdeep","family":"Khattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Kirichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Okines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.S.","family":"Furness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"issue":"6382","key":"147_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. Doi:https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"issue":"12","key":"147_CR2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. Doi:https:\/\/doi.org\/10.1016\/s1470-2045(18)30608-9.","journal-title":"Lancet Oncol"},{"issue":"1","key":"147_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/circulationaha.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem J-E, et al. Myocarditis in the Setting of Cancer Therapeutics Circulation. 2019;140(1):80\u201391. Doi:https:\/\/doi.org\/10.1161\/circulationaha.118.034497.","journal-title":"Myocarditis in the Setting of Cancer Therapeutics Circulation"},{"issue":"5","key":"147_CR4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"J-R Hu","year":"2019","unstructured":"Hu J-R, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854\u201368. Doi:https:\/\/doi.org\/10.1093\/cvr\/cvz026.","journal-title":"Cardiovasc Res"},{"issue":"41","key":"147_CR5","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstr\u00f6m-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathThe Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793\u2013867. Doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehv316.","journal-title":"Eur Heart J"},{"issue":"5","key":"147_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"J Brugada","year":"2019","unstructured":"Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2019;41(5):655\u2013720. Doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehz467.","journal-title":"Eur Heart J"},{"issue":"5","key":"147_CR7","doi-asserted-by":"publisher","first-page":"ehaa612","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):ehaa612. Doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"12","key":"147_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor\u2013Associated Myocarditis. J Am Coll Cardiol. 2021;77(12):1503\u201316. Doi:https:\/\/doi.org\/10.1016\/j.jacc.2021.01.050.","journal-title":"J Am Coll Cardiol"},{"issue":"6165","key":"147_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Cancer. Immunotherapy Sci. 2013;342(6165):1432\u20133. Doi:https:\/\/doi.org\/10.1126\/science.342.6165.1432.","journal-title":"Immunotherapy Sci"},{"issue":"2","key":"147_CR10","doi-asserted-by":"publisher","first-page":"e001754","DOI":"10.1136\/jitc-2020-001754","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2):e001754. Doi:https:\/\/doi.org\/10.1136\/jitc-2020-001754.","journal-title":"J Immunother Cancer"},{"issue":"18","key":"147_CR11","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/nejmoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New Engl J Medicine. 2016;375(18):1749\u201355. Doi:https:\/\/doi.org\/10.1056\/nejmoa1609214.","journal-title":"New Engl J Medicine"},{"issue":"20","key":"147_CR12","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"H-M Chang","year":"2017","unstructured":"Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017;70(20):2536\u201351. Doi:https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1096.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"147_CR13","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/jaha.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. Doi:https:\/\/doi.org\/10.1161\/jaha.119.013757.","journal-title":"J Am Heart Assoc"},{"key":"147_CR14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","volume":"10","author":"Y-W Zhou","year":"2019","unstructured":"Zhou Y-W, Zhu Y-J, Wang M-N, et al. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Front Pharmacol. 2019;10:1350. Doi:https:\/\/doi.org\/10.3389\/fphar.2019.01350.","journal-title":"Front Pharmacol"},{"issue":"18","key":"147_CR15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733\u201343. Doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051.","journal-title":"Eur Heart J"},{"key":"147_CR16","doi-asserted-by":"publisher","unstructured":"Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2021:ehab674-. Doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehab674.","DOI":"10.1093\/eurheartj\/ehab674"},{"issue":"11","key":"147_CR17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio\u2010Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966\u201383. Doi:https:\/\/doi.org\/10.1002\/ejhf.2017.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"147_CR18","doi-asserted-by":"publisher","first-page":"e002553","DOI":"10.1136\/jitc-2021-002553","volume":"9","author":"I Puzanov","year":"2021","unstructured":"Puzanov I, Subramanian P, Yatsynovich YV, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021;9(6):e002553. Doi:https:\/\/doi.org\/10.1136\/jitc-2021-002553.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"147_CR19","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Hear J Cardiovasc Imaging. 2022;23(10):e333\u2013465. Doi:https:\/\/doi.org\/10.1093\/ehjci\/jeac106.","journal-title":"Eur Hear J Cardiovasc Imaging"},{"issue":"10","key":"147_CR20","doi-asserted-by":"publisher","first-page":"e003594","DOI":"10.1136\/jitc-2021-003594","volume":"9","author":"S Boughdad","year":"2021","unstructured":"Boughdad S, Latifyan S, Fenwick C, et al. 68Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer. 2021;9(10):e003594. Doi:https:\/\/doi.org\/10.1136\/jitc-2021-003594.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"147_CR21","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. Doi:https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"147_CR22","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/circulationaha.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor\u2013Related Cardiotoxicity. Circulation. 2017;136(21):2085\u20137. Doi:https:\/\/doi.org\/10.1161\/circulationaha.117.030571.","journal-title":"Circulation"},{"issue":"24","key":"147_CR23","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/circulationaha.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, et al. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor\u2013Associated Myocarditis. Circulation. 2020;141(24):2031\u20134. Doi:https:\/\/doi.org\/10.1161\/circulationaha.119.044703.","journal-title":"Circulation"},{"issue":"5502","key":"147_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science. 2001;291(5502):319\u201322. Doi:https:\/\/doi.org\/10.1126\/science.291.5502.319.","journal-title":"Science"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-022-00147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-022-00147-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-022-00147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:21:46Z","timestamp":1669296106000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-022-00147-w"}},"subtitle":["Including myocarditis and the new entity of non inflammatory left ventricular dysfunction"],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1186\/s40959-022-00147-w","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational retrospective study, the STROBE guidelines and checklist, for cohort studies, were followed. No prior ethical approval or patients\u2019 consent were needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"ARL has received speaker, advisory board or consultancy fees and\/or research grants from Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Janssens-Cilag Ltd, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"21"}}